CT-CIDRA-MINERALS
CiDRA Minerals Processing Inc. (“CiDRA”) and OZ Minerals Ltd (“OZ Minerals”) are pleased to announce that they have entered into a Memorandum of Understanding that provides a basis of common understanding to commission a Front End Engineering Design (FEED) study for customization and tie-in of CiDRA’s proprietary mineral separation technology for operation in a grind circuit rougher application at OZ Minerals’ Carrapateena Mine Site. At the same time, CiDRA and OZ Minerals have agreed to deploy a demonstration plant based on CiDRA’s technology at the site. CiDRA and OZ Minerals share a desire to increase the technology readiness level (TRL) for a commercial scale implementation of CiDRA’s technology as a grind circuit rougher which will process a coarse fraction of the primary grind hydrocyclone underflow at Carrapateena. The goals of the Partnership are to increase plant throughput, recovery, and net metal production at a reduced specific energy consumption in keeping with their efforts to help meet the world’s raw material needs in a responsible, equitable, and sustainable way.
“We are excited to take this next step in our relationship with OZ Minerals. Since early 2022, we have been working closely with the Carrapateena Mine Site to evaluate the potential benefits of CiDRA’s technology. This new technology enables a robust process that can recover mineral particles across a size range from ultra-fine to very coarse with high selectivity and minimal hydraulic entrainment. Applying CiDRA’s novel technology as a grind circuit rougher unlocks the concentrator’s throughput capacity while maintaining world class mineral recovery. The MOU will allow us to collectively focus our efforts to leverage this incredible innovation to enhance the net metal production of the Carrapateena Mine Site and create a tremendous value for each of our companies,” stated Paul Rothman, President of CiDRA.
Joe Seppelt, Manager-Processing at OZ Minerals’ Carrapateena Mine Site stated: “The CiDRA technology can enable us to increase our plant throughput without sacrificing the industry leading recoveries that we have been able to achieve at Carrapateena. This capital efficient approach has the potential to operate with less water and energy and with a smaller footprint. We look forward to working with CiDRA to realize the benefits of their innovation.”
About CiDRA Minerals Processing
CiDRA Minerals Processing develops advanced technologies and solutions that create new paradigms in the minerals processing industry with a focus on increasing enterprise value through optimization, increased recoveries and enhancing the sustainability of limited and valuable resources. CiDRA Minerals Processing provides measurement and control solutions to over 460 mine sites in 46 countries.
About OZ Minerals
At OZ Minerals we strive to be modern. We’re guided by our purpose, “Going beyond what’s possible to make lives better”. We believe that only when we create value for all our stakeholders will we be successful and sustainable. Our framework of systems and behaviours we call The OZWay, guides us while giving us the freedom and pathways to achieve our aspirations and purpose. We are passionate about creating an inclusive culture where people challenge, innovate, learn and grow together. By ethically and responsibly exploring for and mining copper we contribute to a low carbon future and economic wellbeing which, in turn, helps us achieve our purpose and contribute to a better future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom